Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine by Conway, James R.W. et al.
  1Conway JRW, et al. Gut 2018;0:1–17. doi:10.1136/gutjnl-2018-316822
Recent advances in basic science
Combating pancreatic cancer with PI3K pathway 
inhibitors in the era of personalised medicine
James RW Conway,1 David Herrmann,1,2 TR Jeffry Evans,3,4 Jennifer P Morton,3,4 
Paul Timpson1,2
To cite: Conway JRW, 
Herrmann D, Evans TRJ, et al. 
Gut Epub ahead of print: 
[please include Day Month 
Year]. doi:10.1136/
gutjnl-2018-316822
1Garvan Institute of Medical 
Research & The Kinghorn Cancer 
Centre, Cancer Division, Sydney, 
New South Wales, Australia
2St Vincent’s Clinical School, 
Faculty of Medicine, University 
of New South Wales, Sydney, 
New South Wales, Australia
3Cancer Department, Cancer 
Research UK Beatson Institute, 
Glasgow, UK
4Institute of Cancer Sciences, 
University of Glasgow, Glasgow, 
UK
Correspondence to
Dr Paul Timpson, Cancer 
Research Program, Garvan 
Institute of Medical Research, 
Darlinghurst, New South Wales 
2010, Australia;  p. timpson@ 
garvan. org. au
Received 12 June 2018
Revised 2 October 2018
Accepted 4 October 2018
© Author(s) (or their 
employer(s)) 2018. Re-use 
permitted under CC BY. 
Published by BMJ.
AbsTRACT
Pancreatic ductal adenocarcinoma (PDAC) is among the 
most deadly solid tumours. This is due to a generally 
late-stage diagnosis of a primarily treatment-refractory 
disease. Several large-scale sequencing and mass 
spectrometry approaches have identified key drivers 
of this disease and in doing so highlighted the vast 
heterogeneity of lower frequency mutations that make 
clinical trials of targeted agents in unselected patients 
increasingly futile. There is a clear need for improved 
biomarkers to guide effective targeted therapies, with 
biomarker-driven clinical trials for personalised medicine 
becoming increasingly common in several cancers. 
Interestingly, many of the aberrant signalling pathways 
in PDAC rely on downstream signal transduction 
through the mitogen-activated protein kinase and 
phosphoinositide 3-kinase (PI3K) pathways, which has 
led to the development of several approaches to target 
these key regulators, primarily as combination therapies. 
The following review discusses the trend of PDAC 
therapy towards molecular subtyping for biomarker-
driven personalised therapies, highlighting the key 
pathways under investigation and their relationship to 
the PI3K pathway.
InTRoduCTIon
Accounting for ~95% of pancreatic cancers, 
pancreatic ductal adenocarcinoma (PDAC) has 
a very poor overall 5-year survival of 8% and 
is predicted to be the second leading cause of 
cancer-related deaths in the developed world by 
2030.1–3 This has only marginally improved since 
the introduction of gemcitabine in 1995.4 5 Surgery 
remains the only curative treatment and is often 
applied with adjuvant chemotherapy, but as few 
as 10%–15% of patients are eligible at initial diag-
nosis.6–9 Most patients with PDAC have few or 
non-specific symptoms as the tumour develops, 
and this means that a large proportion are diag-
nosed at a late stage, already presenting with 
locally advanced or metastatic disease.10 For those 
patients that are not immediately eligible for resec-
tion, neoadjuvant chemotherapy can be given to 
reduce borderline tumours prior to resection.11 
Recent clinical trials aimed at improving response 
to chemotherapy have demonstrated improved 
survival with patients treated with either a combi-
nation of gemcitabine and nab-paclitaxel or FOLF-
IRINOX (folinic acid, 5-fluorouracil, irinotecan, 
and oxaliplatin).12–16 However, patient tolerability 
may be limited with such aggressive treatment regi-
mens.16 While improvements in surgical techniques 
and chemotherapy regimens are providing modest 
improvements in survival, there is a clear need to 
better understand this aggressive disease to facili-
tate both earlier diagnosis and elucidate new targets 
for combination therapies.
PdAC progression model
The most widely accepted model for PDAC devel-
opment is the progression model, in which PDAC 
originates from preinvasive pancreatic intraepithe-
lial neoplasms (PanINs), which occur in distinct 
pathological stages, namely PanIN-1A, PanIN-1B, 
PanIN-2 and PanIN-3.17–19 In the early stages (ie, 
PanIN-1A and PanIN-1B or low-grade), a muci-
nous epithelium replaces the typically cuboidal 
morphology of normal pancreatic ducts, with a 
low level of dysplasia.19–22 Yet, recent work has 
suggested that pancreatic repair after injury, by the 
process of acinar-to-ductal metaplasia, may also be 
involved in PDAC initiation.23–25 As these PanINs 
progress (ie, to PanIN-2 and PanIN-3 or interme-
diate-grade and high-grade, respectively), dysplasia 
increases and is detectable as nuclear irregularity, 
loss of cell polarity and an increase in intraluminal 
apoptotic debris.19–22 This progression towards 
an invasive carcinoma has been shown to occur 
in parallel with increased proliferation and muta-
tional burden from early preinvasive PanIN stages 
to metastatic PDAC (figure 1).19 26 Importantly, a 
mechanism underlying the switch from PanIN to 
metastatic PDAC remains unclear, but new geneti-
cally engineered mice that model multistep carcino-
genesis may support the widely accepted stepwise 
mutational model, where some have suggested that 
catastrophic genomic events may instead trigger the 
transformation from preneoplastic lesions.27 28
A similar progression model has been proposed 
for intraductal papillary mucinous neoplasms 
(IPMNs), which are generally benign, but progress 
to an invasive carcinoma in up to 25% of cases.29–32 
Both IPMNs and mucinous cystic neoplasms are 
radiologically detectable as macroscopic lesions and 
are classified according to the Sendai guidelines.33 
They are typically distinguished from PDAC at a 
macroscopic level by mucoid contents and have 
distinct stromal subtypes at a microscopic level.34 35 
Indeed, the mucoid expression itself has been used 
to subtype IPMNs according to whether the gene 
expression is gastric or intestinal, which clearly 
distinguished aggressive disease as the intestinal 
subtype.35
Attempts have been made to classify PanINs in 
terms of their mutational burden. Initially, evidence 
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of telomere shortening and mutations in KRAS were found to 
occur very early in PanIN progression.36 37 This excluded KRAS 
as a potential marker for PDAC progression but highlights the 
general classification as the earliest initiator mutation in PDAC, 
occurring in ~95% of PDAC cases.26 38 Progression through 
to PanIN-2 and PanIN-3 typically includes additional muta-
tions in TP53, SMAD4 and/or CDKN2A, but the vast molecular 
heterogeneity of this disease precludes any single mutation as 
essential for PDAC development.38 39 With this in mind, several 
large-scale sequencing and mass spectrometry approaches have 
been implemented to subtype the disease based on these molec-
ular characteristics.40–43 The goal of such work is to better 
integrate biomarkers into the drug discovery pipeline, where 
lead compound development is performed hand in hand with 
biomarker identification (figure 2). This parallel preclinical 
development aims to foster a more personalised approach to 
clinical trial development, whereby each patient may be assessed 
for their respective molecular subtype and treatment is designed 
based on this result (figure 2).
Molecular subtyping of PdAC
While several mutations occur at relatively high frequency in 
PDAC, mutations in the aforementioned genes are not currently 
associated with clinically actionable phenotypes. The milieu of 
lower frequency mutations, however, has motivated subtyping 
based on commonly mutated biological processes, termed gene 
programmes (GPs). The aim of such work is to develop ther-
apeutic strategies that are selectively effective against specific 
tumour subtypes.15 44 Early work stratified PDAC according to 
an activated stromal index, which classified patients according 
to the ratio of alpha smooth muscle actin (immunohisto-
chemical (IHC) staining) and collagen (stained with the colla-
gen-specific Aniline blue).45 Such an index informs primarily on 
stromal targeting and alone is not sufficient to guide therapies 
aimed at complete tumour regression. Indeed, a second study 
took the opposite approach and removed the stroma by laser 
microdissection from the PDAC samples, prior to microarray 
analysis and subtyping of PDAC based on multivariate analysis 
of transcriptional profiles, namely classical, exocrine-like and 
quasimesenchymal (QM; table 1, see column ‘Collisson’).40 Such 
an approach allowed the authors to identify neoplastic epithe-
lial-specific gene expression and to identify pathways involved 
in PDAC progression. This approach also motivated metabolite 
profiling within these subtypes, where classical tumours were 
shown to be lipogenic, while QM tumours were glycolytic.46 
With clear subtype-specific metabolic targets, new avenues 
for combination therapies within a personalised setting are an 
obvious progression to improve patient responses. Additionally, 
increasing evidence for the importance of the stroma in disease 
progression means assessment of either the tumour or stroma 
in isolation is likely to be too simplistic to provide any lasting 
improvements in patient survival.47
Figure 1 Schematic representation of PDAC progression from the primary tumour to a locally invasive disease and eventually metastasis. (1) 
Pancreatic cancer cells proliferate in the primary tumour, metabolising nutrients delivered by the blood vasculature and surrounding stroma. (2) 
Cancer cells invade through the extracellular matrix (ECM), including cancer-associated fibroblasts (CAFs) and tumour-associated macrophages 
(TAMs), among other cancer-associated cell types, eventually intravasating or invading into the lymph and travelling to distant sites. (3) Circulating 
tumour cells (CTCs) must develop resistance to anoikis, as well as shear stress, in order to survive in the circulation with red blood cells (RBCs) and 
leucocytes. (4) After travelling through the circulation, CTCs extravasate at secondary sites, commonly the liver, establishing a new niche. ECM, 
extracellular matrix; PDAC, pancreatic ductal adenocarcinoma.
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Physical microdissection approaches rely on IHC to inform 
stromal activation state and also limit the application of patient 
subtyping by molecular approaches due to a low sample 
throughput and smaller sample volume.48 As large datasets 
become increasingly common, new analytical approaches 
improve the readouts incurred. A more recent approach to 
PDAC subtyping involved virtual microdissection of large 
microarray datasets, facilitating molecular subtyping of both the 
tumour and the stroma.41 Using multivariate analysis to distin-
guish tumour and stromal components, the tumour was split 
into a classical and more aggressive basal-like subtype, and the 
stroma was classified into activated or normal subtypes (table 1, 
see column ‘Moffit’). This additional stromal subtyping was 
also recently applied to PDAC patient-derived xenograft (PDX) 
tumours, whereby tumours classified as basal or classical were 
shown to have an ‘echo’ in the mouse stroma.49 They further 
demonstrated the power of their classifications through inhibi-
tion of cholesterol uptake in subtyped PDX models, where basal 
tumours were highly sensitive to inhibition, but classical tumours 
were shown to have higher NPC1L1 expression and may require 
a greater concentration of inhibitor to achieve an equivalent 
growth inhibition.
Further subtyping was recently performed on a 328 primary 
patient PDAC cohort using expression analysis from RNAseq (96 
patients) and microarrays (232 patients).42 This study included 
samples with invasive IPMN-associated PDACs and some meta-
static tumours and, in contrast to the previous studies, applied 
macrodissection to excise areas of nonmalignant tissue, main-
taining the stromal component in each sample.38 42 50 Tumour 
purity could then be inferred in terms of stromal and immune 
infiltration based on the Estimation of STromal and Immune cells 
in MAlignant Tumor tissues using Expression data approach.51 
Beyond purity assessment, this approach facilitated assessment 
of GPs associated with microenvironmental factors, such as 
hypoxia, ECM deposition and activated immune pathways.42 
The microenvironmental influence on cancer progression is an 
essential consideration for emerging therapies, where immune 
cells, cancer-associated fibroblasts and ECM components are 
regularly associated with cancer progression (figure 1). Inclu-
sion of this stromal contribution, as well as the large breadth 
of patient samples, allowed the authors to reclassify PDAC 
into four distinct subtypes (summarised in table 1 (see column 
‘Bailey’) and box 1). This is particularly important in light of the 
high attrition rates for lead compounds currently experienced 
by the pharmaceutical industry, where more detailed molecular 
analysis prior to treatment is expected to improve both patient 
and trial outcomes (figure 2).52–54
The goal of this molecular phenotyping is to establish trials, 
such as IMPaCT, PRECISION-Panc, SHIVA, or biomarker-driven 
Figure 2 Adaptable drug development pipeline, demonstrating the progression of lead compounds through target validation, lead compound 
identification and optimisation, then preclinical validation. The necessary addition to this process is the identification of biomarkers to guide both lead 
compound development and later stratification in phase II/III clinical trials. These processes may be iterated to improve on-target efficacy, solubility 
and biomarkers. After safety and tolerability is confirmed in phase I clinical trials, biomarker-driven phase II/III may reduce the high attrition rates of 
lead compounds if appropriate patient stratification can demonstrate beneficial response in the assessed subsets of patients. These biomarkers may 
also provide opportunities for retrospective analysis and later iteration into clinical trials. PI3K, phosphoinositide 3-kinase.
Table 1 Molecular subtyping of patients with pancreatic cancer
Collisson Moffit bailey
Approach Microarray Microarray Expression analysis 
(RNAseq and 
microarray)
Cohort 63 primary 
resected PDAC
145 primary resected 
and 61 metastatic 
PDAC tumours
96 RNAseq and
242 microarray 
primary patient 
samples
Tumour/stromal 
contribution
Microdissection Multivariate 
analysis (virtual 
microdissection)
Macrodissection
Tumour subtypes Classical Classical Pancreatic progenitor
Immunogenic
Exocrine-like ADEX
QM Basal like Squamous
Stromal subtypes Not assessed Activated ESTIMATE
Normal
This pancreatic cancer subtype table is adapted from refs 40–42.
ADEX, Aberrantly Differentiated Endocrine eXocrine; ESTIMATE, Estimation of 
STromal and Immune cells in MAlignant Tumor tissues using Expression data; PDAC, 
pancreatic ductal adenocarcinoma; QM, quasimesenchymal. 
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avatar trials (NCT02795650), where actionable molecular data 
guides therapies.55 56 These trials have established the feasi-
bility of biopsy collection for pancreatic cancer within a clin-
ical setting, where molecular assessment was performed by IHC 
or genomic approaches. However, biomarker-driven trials for 
pancreatic cancer remain infrequent, despite increasing evidence 
for a lack of stratification leading to late-stage failure. This is 
particularly evident for PI3K pathway inhibitors, where preclin-
ical efficacy is driving their assessment in a clinical setting, but 
biomarker-driven trials in pancreatic cancer are sorely lacking 
(table 2). This is in stark contrast to the increase in biomark-
er-driven trials in other cancers, where biomarkers such as loss 
of phosphatase and tensin homolog (PTEN), PIK3CA mutation 
or Akt amplification/mutation are increasingly used to stratify 
patients for treatment with PI3K pathway inhibitors.57 Further 
to this goal, the subtyping approaches described above may also 
provide novel clinically actionable biomarkers or GPs to allow 
patient-selective assessment of PI3K pathway inhibitors to push 
PDAC survival beyond the current standard of care.
The PhosPhoInosITIde 3-kInAse (PI3k) PAThwAy
A broad range of cancer types, including pancreatic cancer, 
have been candidates for targeting of the PI3K pathway, due to 
amplification, mutation or loss of key regulators.58 59 The PI3K 
pathway mediates transduction of signals from both extracel-
lular and intracellular sources, including growth factors and 
nutrients, leading to downstream signalling involved in cancer 
growth, survival and progression (figure 1).58 60 61 The pathway 
is also essential for many cancer-associated activities, including 
endothelial cell sprouting for angiogenesis, macrophage tran-
scriptional reprogramming, T cell differentiation and homeo-
stasis and fibroblast-supported chemoresistance (figure 1).62–65 
Collectively, this suggests that application of PI3K pathway 
inhibitors as a PDAC therapy may provide an opportunity for 
dual targeting of cancer cells and the deregulated cancer-associ-
ated stromal components.
PDAC is regularly associated with increased Akt activity, which 
has been identified in ~60% of PDAC samples, with amplifica-
tion of the AKT2 oncogene occurring in 10%–20% of PDAC 
cases.66–68 Akt is a key effector of the PI3K pathway, downstream 
of both PI3K and receptor tyrosine kinases (RTKs; table 2). 
Furthermore, PDAC tumours have been shown to bear an acti-
vating mutation in PIK3CA and/or loss of the tumour suppressor 
PTEN in ~4% and 25%–70% of cases, respectively.50 69–72 Inter-
estingly, patients with low PTEN expression have a much higher 
incidence of recurrence or metastasis, compared with those 
with high PTEN.72 Furthermore, it has been shown that PDAC 
patients with high PI3K pathway activity show a significantly 
poorer survival than those with low activation of this pathway.73
Several signalling pathways are known to converge on the 
MAPK and PI3K pathways as effectors of cellular response 
within the cell. For example, in ~95% of cases, pancreatic cancer 
is driven by activating mutations in KRAS, which in turn activates 
PI3K signalling through the p110α subunit, along with another 
pathway component PDK1, indicating that a large proportion of 
patients could benefit from effective targeting of this pathway 
(figure 3).28 73–76 Furthermore, detection of mutations in PIK3CA 
can be predictive for improved patient response in preclinical 
models of PDAC and in patients with breast cancer stratified 
according to detection of mutations in circulating cell-free 
DNA.74 77–79 Given the varied roles of different PI3K isoforms 
in both the tumour and associated stromal cells, isoform-specific 
inhibitors provide isolated targeting of oncogenic signalling and 
allow redundancy to alleviate off-target side effects in healthy 
tissues (table 2; reviewed in refs 80 81). Notably, a PI3Kα-spe-
cific inhibitor has shown promising efficacy in combination with 
an EGFRi in PDAC with high EGFR and Akt phosphorylation.82 
Interestingly, PIK3CA mutations in breast cancer have also been 
linked with Akt-independent tumour progression through SGK3 
and highlight the importance of all levels of this key signalling 
cascade.83 Similarly, isoform-specific PI3Kβ inhibition extended 
PDAC survival beyond mTORC1/2 targeting alone,84 and in other 
cancers, inhibition of PI3Kβ and PI3Kδ has shown antimetastatic 
effects and suggests a role of PI3K in tumour metastatic dissem-
ination.85 86 Furthermore, isoform-specific inhibition of PI3Kδ 
in cancer-associated immune cells was shown to downregulate 
their tolerance to PDAC, which improved the activity of T cells 
against the cancer.87 Collectively, we see strong evidence accu-
mulating for the efficacy of upstream isoform-specific targeting 
of PI3K in emerging PDAC combination therapies.
box 1 Pancreatic cancer subtypes
Molecular subtypes (described in ref 42)
Immunogenic
Patients were classified with this subtype if they showed 
evidence of high levels of immune infiltrate, which presents an 
inferred opportunity for emerging immunotherapies.
Pancreatic progenitor
This subtype shares several gene programmes (GPs) with the 
immunogenic subtype. It is defined by an increased activity of 
transcriptional networks associated with pancreatic endodermal 
cell fate. Pancreatic ductal adenocarcinoma (PDAC) associated 
with IPMN typically fell within this subtype, where an increase in 
fatty acid metabolism and O-linked glycosylation of mucins was 
upregulated.
Aberrantly Differentiated Endocrine eXocrine
This subtype presented with higher activity of GPs associated 
with exocrine secretion, consistent with a more differentiated 
pancreatic lineage.
Squamous
Describing the most aggressive PDAC tumours, including 
the KPC GEM PDAC model, this subtype is defined by an 
upregulation of GPs associated with hypoxia, metabolic 
reprogramming, ECM deposition, squamous differentiation and 
proliferation.
neoantigen quality (described in ref 280)
Antigens encoded by tumour-specific genes (neoantigens) 
are enriched in long-term PDAC survivors, along with high T 
cell infiltration. The quality of neoantigen may then provide a 
biomarker for emerging immunotherapies.
Mass spectrometry subtypes (described in ref 43)
Using 8 or 33 phosphosites as classifiers, the Australian 
Pancreatic Cancer Genome Initiative patient-derived cell lines 
or commercially available pancreatic cancer lines from the 
American Type Culture Collection were grouped into three 
subtypes based on their pTyr levels. Of these, subtype 3 in 
both cell line cohorts was enriched for receptor tyrosine kinase 
(RTK) phosphorylation and showed increased sensitivity 
to the epidermal growth factor receptor inhibitor erlotinib. 
This suggests that mass spectrometry approaches may 
provide a binary system for classifying patients into RTK or 
phosphoinositide 3-kinase pathway targeted therapies.
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Table 2 List of PI3K pathway inhibitors currently undergoing clinical development for pancreatic cancer
Target Inhibitor Phase status Patients Combination nIh number Reference(s)
Akt inhibitors
  Pan-Akt MK2206 I Completed AdvST/MST
(~9% pancreatic cancer)
Monotherapy NCT00670488 262 263
I Completed AdvST/MST Selumitinib (MEKi) NCT01021748
I Completed PDAC (PTEN loss) Monotherapy NCT00848718 264
I Completed Pancreatic cancer Dinaciclib (CDKi) NCT01783171
II Completed Pancreatic cancer Selumitinib (MEKi)
versus mFOLFOX6
NCT01658943 265
Afuresertib 
(GSK2110183)
I Completed AdvST
(21% pancreatic cancer)
Trametinib (MEKi) NCT01476137 266
II Ongoing AdvST NCT01531894
Uprosertib 
(GSK2141795)
I Completed Pancreatic cancer Trametinib (MEKi) NCT01138085
I Completed AdvST NCT00920257
Oleandrin (PBI-05204) I Completed AdvST
(6% pancreatic cancer)
NCT00554268 267
II Ongoing Metastatic pancreatic cancer NCT02329717
Perifosine II Completed Locally advanced or 
metastatic pancreatic cancer
NCT00053924
II Completed Locally advanced or 
metastatic pancreatic cancer
NCT00059982 268
RX-0201 II Completed Metastatic pancreatic cancer Gemcitabine NCT01028495
Rapalogs
  mTORC1 
(FKBP12)
Sirolimus (rapamycin) I Completed Pancreatic cancer Sunitinib (RTKi) NCT00583063 150
I Completed Pancreatic cancer Sorafenib (RTKi) NCT00449280 150
II Completed Pancreatic cancer NCT00499486
II Completed Pancreatic cancer NCT00276744
I/II Ongoing PDAC Metformin NCT02048384
I Ongoing Pancreatic cancer Vismodegib (SMOi) NCT01537107
Temsirolimus (CCI-779, 
Torisel)
I Completed Pancreatic cancer Lenalidomide NCT01183663
I Terminated PDAC Gemcitabine NCT00593008
I/II Ongoing Pancreatic cancer Nivolumab (PD-1i) NCT02423954
II Completed Locally advanced or 
metastatic pancreatic  
cancer
NCT00075647 95
Everolimus (RAD001) I Completed Pancreatic cancer Sorafenib (RTKi) NCT00981162
I Completed Pancreatic cancer Trametinib (MEKi) NCT00955773 269
I/II Completed PDAC Gemcitabine NCT00560963
I/II Completed Pancreatic cancer Cetuximab (EGFRi) 
and capecitabine
NCT01077986 99
II Terminated Pancreatic cancer Erlotinib (EGFRi) NCT00640978 95
II Completed Pancreatic cancer NCT00409292 94
I/II Recruiting PDAC Ribociclib (CDKi) NCT02985125
Ridafirolimus I Completed AdvST
(12% pancreatic  
cancer)
Bevacizumab 
(VEGFRi)
NCT00781846 149
PI3K inhibitors
  PI3K isoform 
p110α
Alpelisib (BYL719) I Ongoing Pancreatic cancer Gemcitabine and 
abraxane
NCT02155088
  Pan-PI3K Buparlisib (BKM120) I Completed Pancreatic cancer mFOLFOX6 NCT01571024 270
I Completed Pancreatic cancer LDE225 (SMOi) NCT01576666
I Completed Pancreatic cancer Trametinib (MEKi) NCT01155453 271
I Ongoing AdvST MEK163 (MEKi) NCT01363232
PX-866 I Completed AdvST
(5% PDAC)
Docetaxel NCT01204099 272
ZSTK474 I Completed AdvST NCT01280487
Copanlisib
(BAY 80–6946)
I Completed AdvST
(18% pancreatic cancer)
NCT00962611 273
Continued
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Concordantly, evidence for the validity of downstream 
pathway targeting is highlighted in a genetically engineered 
mouse model of mutant KrasG12D-driven PDAC, which was 
applied in concert with a sleeping beauty transposon library, 
both conditionally expressed (ie, LSL-KrasG12D and LSL-SB11) 
under pancreas-specific Pdx1-Cre.88 89 These approaches identi-
fied several genes within the MAPK and PI3K pathways as coop-
erating mutations for KrasG12D-driven PDAC. Similarly, recent 
assessment of kinases with the highest levels of absolute and 
differential expression in a panel of pancreatic cancer cell lines 
demonstrated significantly reduced cell number after knock-
down of EGFR, Akt2, PLK2 or MET.90 This review will focus on 
PI3K pathway targeting in PDAC (see also table 2, PI3K pathway 
inhibitors under clinical investigation in PDAC).
PI3k pathway inhibitors in the clinic
After the discovery and isolation of rapamycin on the island of 
Rapa Nui from Streptomyces hygroscopicus, over 30 years of 
research continues to find new therapeutic applications for this 
compound.91 For example, the mTOR inhibitor (mTORi) rapa-
mycin was recently assessed in PDAC driven by activated PI3K/
AKT signalling via PTEN loss, where targeting of mTORC1 by 
rapamycin significantly reduced the onset and progression of the 
disease (figure 3).92 Work to improve the solubility and bioavail-
ability of rapamycin-based compounds (rapalogs) has seen modi-
fication at the C-42 position through addition of an ester, ether 
or phosphonate group to generate temsirolimus, everolimus and 
ridaforolimus, respectively.60 Clinical trials in pancreatic neuro-
endocrine tumours (pNETs) have demonstrated a clear benefit 
for rapalogs as single agents (table 2);93 however, no significant 
improvements have been identified for rapalogs as single agents 
in PDAC.94 95 This has been attributed to an upstream feedback 
loop where inhibition of mTORC1 alone relieves the inhibitory 
phosphorylation of insulin receptor substrate 1 (IRS1)by p70-S6K 
and mTORC1, leading to an upregulation of Akt phosphoryla-
tion (figure 3).96 97 Hence, while trials of rapalogs may benefit 
from stratification for patients with high PI3K pathway activity, 
newer agents that target both mTORC1 and mTORC2, or other 
pathway components, allow the negation of this feedback loop 
with promising therapeutic potential (table 2).84 98 Importantly, 
new combination therapies with rapalogs should consider the 
combined toxicity with other targeted compounds. For example, 
combination of everolimus with the RTKi cetuximab was found 
to be too toxic for patients with PDAC in a phase I/II clinical 
trial, while the single agents show minimal toxicity.94 99 100 With 
this in mind, trials are still ongoing in PDAC using rapalogs in 
combination therapies (table 2).
Next-generation dual PI3K pathway inhibitors are being 
developed that take advantage of the homology of the kinase 
domains from class I, II and III PI3Ks and those of phosphoinos-
itide 3-kinase-related kinases, such as mTOR, ATM and DNA-PK 
(figure 3, table 2).101 However, these dual inhibitors have been 
linked with drug-related dosage-dependent toxicities, such as 
hyperglycaemia, nausea, vomiting and diarrhoea, consistent with 
PI3K isoform targeting, and reinforce the need for preclinical 
assessment of the additive or synergistic toxicities when devel-
oping novel combination therapies.81 Moving forward, improve-
ments in solubility are driving greater oral bioavailability, 
Target Inhibitor Phase status Patients Combination nIh number Reference(s)
Dual PI3K pathway inhibitors
  mTORC1/2 Vistusertib (AZD2014) I Completed AdvST NCT01026402 98
II Recruiting AdvST (RICTOR amplified) NCT03166904
II Recruiting AdvST:
combination with 
Selumitinib (MEKi)
NCT02583542
II Recruiting AdvST (TSC1/2 loss or 
mutation)
NCT03166176
II Recruiting AdvST:
combination with Olaparib 
(PARPi)
NCT02576444
  p70-S6K and Akt LY2780301 I Complete AdvST
(~22% pancreatic cancer)
NCT01115751 274
  PI3K and mTOR Dactolisib
(NVP-BEZ235)
I Completed AdvST MEK162 (MEKi) NCT01337765
NVP-BGT226 I Completed AdvST
(2% pancreatic cancer)
NCT00600275 275
Voxtalisib (SAR245409, 
XL765)
I Completed AdvST
(4% pancreatic cancer)
NCT00485719 276
SF1126
(LY294002 prodrug)
I Completed AdvST
(5% pancreatic cancer)
NCT00907205 277
Gedatolisib (PF-
05212384, PKI-587)
I Terminated AdvST
(5% pancreatic cancer)
Irinotecan NCT01347866 278
I Completed AdvST
(4% PDAC)
NCT00940498 279
I Recruiting AdvST Palbociclib (CDKi) NCT03065062
AdvST, advanced solid tumours (including pancreatic cancer); CDKi, cyclin-dependent kinase inhibitor; EGFR, epidermal growth factor receptor; EGFRi, EGFR inhibitor; 
MEKi, MAPK/ERK kinase inhibitor inhibitor; mFOLFOX6, modified FOLFOX (ie, 5-fluorouracil and oxaliplatin); MST, metastatic solid tumours (including pancreatic 
cancer); mTOR, mechanistic target of rapamycin; NIH, National Institutes of Health; PARP, poly (ADP-ribose) polymerase; PARPi, PARP inhibitors; PDAC, pancreatic 
ductal adenocarcinoma; PD-1, programmed death-1; PD-1i, PD-1 inhibitor; PI3K, phosphoinositide 3-kinase; RTKi, receptor tyrosine kinase inhibitor; SMOi, smoothened 
inhibitor; VEGFRi, vascular endothelial growth factor receptor inhibitor.
Table 2 Continued 
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where lower drug dosages can show equivalent drug efficacy 
and gastrointestinal toxicities are readily reduced.102 103 One 
exciting example of a dual PI3K pathway inhibitor is AZD2014, 
which was developed by iterative structure–activity relation-
ship medicinal chemistry approaches to have high aqueous 
solubility and a potent inhibitory effect against both mTORC1 
and mTORC2.104 Recent preclinical work by our group has 
demonstrated potent antiproliferative and anti-invasive effects 
in the KPC (LSL-KrasG12D, LSL-Trp53R172H and Pdx1-Cre) GEM 
PDAC model84 105 and after a promising phase I clinical trial in 
advanced solid tumours (AdvSTs), AZD2014 has progressed to 
phase II biomarker-driven clinical trials either alone or in combi-
nation with a MAPK/ERK kinase inhibitor (MEKi) (table 2).98 
The additional anti-invasive role for AZD2014 is consistent 
with increasing evidence for the emerging antimetastatic and 
anti-invasive effect of PI3K pathway targeting (figure 1).105–109 
Indeed, the opposing roles for the different Akt isoforms in cell 
motility have identified an invasion and metastasis promoting 
role of Akt2 but an inhibitory role for Akt1.110–114 The dual role 
of Akt1 in either promoting tumour growth or metastasis was 
recently shown to be regulated by the inositol polyphosphate 
5-phosphatase (PIPP), where PIPP ablation resulted in reduced 
metastasis but increased tumour growth.108 Similarly, mTORC1 
and mTORC2 have been shown to regulate migration and 
invasion through Rac1 and RhoA.58 80 115 Furthermore, mTOR 
inhibition dramatically reduced metastasis in prostate cancer, 
highlighting the broader potential of PI3K pathway therapeu-
tics as antimetastatic agents.116 Intriguingly, the mTOR inhib-
itor, everolimus, resulted in a partial response in a patient with 
pancreatic cancer that was induced by Peutz-Jeghers syndrome 
(PJS).117 PJS is caused by a tumour-suppressor gene mutation 
in the serine threonine kinase 11 gene (STK11, also known as 
LKB1), which results in ~11%–36% of patients with PJS devel-
oping pancreatic cancer.117 This loss of STK11 leads to a loss of 
suppression of mTOR signalling and raises the tantalising possi-
bility that mTOR inhibition could have monotherapy efficacy in 
PDAC in selected cases with a similar genetic background.
eMeRgIng oPPoRTunITIes FoR CoMbInATIon TheRAPIes
opportunities for patients with RTk amplification or mutation
The RTK family comprises several subfamilies that are not 
limited to ErbB, fibroblast growth factor receptors (FGFRs), 
insulin and insulin-like growth factor receptors, platelet-derived 
growth factor receptor (PDGFR), vascular endothelial growth 
factor (VEGF) receptor (VEGFR) and Axl and the Ephrin recep-
tors. Inhibition of these receptors using RTK inhibitors (RTKi) 
generally takes one of three forms: antibody or recombinant 
protein inhibition of the extracellular ligand binding domain, 
inhibition of the ligand itself, or targeting of the cytoplasmic 
tyrosine kinase domain.
In recent work, 19 PDAC cell lines from the American Type 
Culture Collection and 17 patient-derived cell lines (PDCLs) 
from the Australian Pancreatic Cancer Genome Initiative collec-
tion, sequenced as part of the International Cancer Genome 
Consortium (ICGC), were used to assess global phosphotyrosine 
(pTyr) profiles in PDAC by mass spectrometry.43 This approach 
allowed the authors to define two sets of classifier mutations (8 
and 33 pTyr sites) that predicted three PDAC subtypes over the 
two cell line panels (box 1). Interestingly, when RTK activity was 
enriched, the cell lines showed an enhanced sensitivity to the 
EGFRi erlotinib, suggesting that this subtyping approach may 
provide a method to stratify patients for RTK-targeted therapies. 
While the somatic mutation profiles did not correlate with the 
pTyr-based subtyping, similar GPs were identified between both 
the genomic and mass spectrometry studies.42 43 However, at the 
mass spectrometry level, it was possible to identify the activa-
tion status of kinase networks and receptors. This lends weight 
Figure 3 Simplified schematic of the PI3K pathway, which highlights the common targets for small molecule inhibitors. Briefly, signalling from 
growth factors activates RTKs and recruits PI3K and other scaffold proteins to the cell membrane, where PIP2 is converted to PIP3. This recruits 
phosphoinositide-dependent kinase-1 (PDK1) and Akt to the membrane and leads to downstream signalling through the kinase activities of Akt. (1) 
Single-strand break repair is regulated primarily by PARP and inhibition of PARP can lead to genomic instability. (2) Double-stranded break repair is 
primarily regulated by a complex with BRCA2, which is lost in familial pancreatic cancer and some PDAC cases and can lead to genomic instability. 
Genomically unstable tumours require the PI3K pathway to maintain survival pathways and PI3K pathway inhibition may be an emerging option 
for patients with BRCA2 mutations or in combination with PARP inhibitors. More exhaustive pathway maps can be found in refs 61 80. P13K, 
phosphoinositide 3-kinase; RTKs, receptor tyrosine kinases.
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to the overlapping use of both genomic and mass spectrometry 
approaches to assess aberrant pathway expression, mutation 
status and, importantly, activation state and provides clear moti-
vation for the incorporation of both techniques into the drug 
discovery pipeline (figure 2).
The ErbB family
RTKs are transmembrane receptors that communicate signals 
from ligands outside of the cell by activating their cytoplasmic 
tyrosine kinase domains, which facilitate downstream signalling 
within the cell, typically through activation of the MAPK and 
PI3K pathways. The ErbB family contains four RTKs structur-
ally related to the epidermal growth factor receptor (EGFR; 
human epidermal growth factor receptor (HER) 1 and ErbB-1). 
EGFR expression is observed in normal pancreatic ducts but has 
been shown to increase from the early stages of PanIN develop-
ment through to PDAC.118–120 Targeting of the EGFR receptor 
with the small molecule inhibitor erlotinib in combination with 
gemcitabine resulted in a statistically significant, but clinically 
modest, improvement in overall survival compared with gemcit-
abine monotherapy in patients with metastatic disease and has 
also been evaluated in the adjuvant setting.121 122 These studies 
subsequently motivated the assessment of predictive markers 
that would stratify patients for this treatment.123–126 These 
studies found conflicting evidence for KRAS mutational status 
as a predictive or prognostic marker for erlotinib response but 
suggested that mutations or amplification of EGFR may be suffi-
cient to stratify patients for therapy. Interestingly, expression of 
ErbB-3 (HER3) has been associated with sensitivity to erlotinib 
treatment in pancreatic cancer cell lines and therefore may prove 
an effective biomarker for adjuvant erlotinib for patients with 
PDAC.127–129 ErbB-3 requires heterodimerisation for downstream 
signalling through the PI3K pathway and expression in PDAC is 
a poor prognostic factor for survival.127–129 Another emerging 
personalised approach to PDAC therapy comes from the success 
of targeting ErbB-2 (neu and HER2) amplified tumours with 
a humanised monoclonal antibody.130 ErbB-2 amplification in 
PDAC has a relatively low prevalence of 2%;50 131 132 however, 
clinical trials with trastuzumab (Herceptin) in combination with 
chemotherapy have shown beneficial responses in metastatic 
PDAC patients with ErbB-2 amplification,133 134 and studies 
are still ongoing in metastatic or recurrent PDAC.56 ErbB-4 
(HER4) is the last member of the ErbB family but is only weakly 
expressed in PDAC.135 136 However, given the established impor-
tance of the other ErbB family members in PDAC progression, 
they may also prove effective biomarkers for inhibition of the 
PI3K pathway, which is less sensitive to changes in receptor 
dimerisation.
FGFR, PDGFR and VEGFR stromal targeted therapies and biomarkers
The FGFR, PDGFR and VEGFR families share sufficient struc-
tural homology that targeting of these receptors often has over-
lapping responses. In PDAC, overactivation of FGFR signalling 
has been associated with 2% of patients, and targeting of this 
receptor in PDAC using dovitinib has recently completed a 
phase I clinical trial in combination with chemotherapy, after a 
promising preclinical study, where dovitinib was found to exert 
its effect through decreased Akt activity (NCT01497392).50 137 
Furthermore, FGFR and PDGFR upregulation in a proof-of-
principle study using Kras-deficient PDAC was recently linked 
with increased sensitivity to PI3K pathway targeting high-
lighting the essential supportive role this pathway plays in 
PDAC progression and the potential of RTKs as biomarkers for 
patient stratification.138 Interestingly, inhibition of FGFR alone 
or in combination with PDGFR inhibition was not sufficient to 
decrease cancer cell proliferation to the same degree as PI3K 
pathway inhibitors, indicating that multiple RTK pathways feed 
into PI3K activation in PDAC and that PI3K inhibition may 
provide an opportunity for targeting of multiple de-regulated 
RTK pathways simultaneously (figure 3).138
Due to the highly desmoplastic reaction characteristic of 
PDAC, it is important to consider the stromal responses to ther-
apies and even look for new targets within this compartment. 
Moreover, the effect of FGFR targeting in stromal pancreatic stel-
late cells has also demonstrated a beneficial outcome by reducing 
cancer cell invasion and hence better containing the tumour.139 
This suggests that PI3K pathway inhibition may also have an 
antistromal effect that reduces the protumourigenic role of the 
activated cancer-associated fibroblasts and stellate cells, but as 
yet, this effect has not been assessed. Interestingly, overexpres-
sion of FGFR has also been used in a less conventional approach, 
where targeting this cell-surface receptor with an antibody-con-
jugated adenovirus specifically delivered a viral gene.140 This 
viral gene then predisposed these cells to antiviral therapy by 
ganciclovir. While this work has not progressed beyond preclin-
ical models, other alternative therapies, such as antibody-conju-
gated nanoparticles, toxins, viruses or CAR-Ts,141–144 highlight 
the variety of emerging therapies that could potentially combat 
this primarily treatment-refractory disease.
PDGFR is less commonly mutated in PDAC, but upregulation 
of PDGFR signalling has been implicated as a mechanism for 
metastatic progression in p53-mutated tumours.42 145 146 Interest-
ingly, one patient with PDAC who responded well to AZD2014 
therapy in a phase I trial was found to have a PDGFR1A muta-
tion, and this may present a novel biomarker for therapies 
aimed at PI3K pathway inhibition.98 An important function of 
PDGFR signalling is an overlapping role with VEGFR signal-
ling for angiogenesis, which has been extensively assessed as a 
target in PDAC.147 After promising clinical trials led to approval 
of the mTORC1 inhibitor rapamycin and the broad-spectrum 
RTKi Sunitinib in pNETs, which are typically highly vascular-
ised, several clinical trials began looking at the effectiveness of 
these inhibitors in PDAC (table 2).93 148 However, the antian-
giogenic effects in PDAC provided minimal clinical benefit and 
future clinical trials are looking at the application of RTKi as 
part of combination therapies (table 2).149–152 One interesting 
target that has emerged from VEGFR targeting strategies is the 
discovery that placental growth factor, a VEGF homologue, is 
specifically upregulated in tumour vasculature and provides a 
target for disease-specific angiogenesis, without affecting normal 
healthy vessels.153 However, the effectiveness of this strategy 
remains controversial and has yet to progress to the clinic.154
Ephrin receptors as predictive biomarkers or novel targets
The largest known RTK family is that of the Ephrin receptors, 
of which both the EphrinA and EphrinB subfamilies are associ-
ated with poorer survival in patients with PDAC and are predic-
tive of tumour proliferative and growth capacity.155 156 Indeed, 
increased activity of EphrinA2 has been associated with Kras-
driven PDAC progression and knockdown in a mouse model of 
PDAC decreased metastasis.43 157 Furthermore, axon guidance 
GPs in which EphrinA5 and EphrinA7 play a role have been 
implicated in PDAC development, providing further motivation 
for application of the EphrinA/EphrinB receptors as predictive 
biomarkers for aggressive disease.38 Their continued associa-
tion with PDAC has led to several approaches to therapeutically 
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target these receptors.158 For example, a recent toxin-conjugated 
monoclonal antibody against the EphrinA2 receptor MEDI-
547 completed phase I clinical trials in treatment-refractory 
solid tumours.159 Similarly, the broad-spectrum small molecule 
tyrosine kinase inhibitor dasatinib has an established inhibitory 
effect on the intracellular kinase domains of Ephrin receptors 
and provides a parallel approach for targeting of other RTKs.160 
After promising preclinical studies, dasatinib has progressed to 
clinical trials for metastatic PDAC in combination with FOLFOX 
(NCT01652976) or gemcitabine/erlotinib (NCT01660971) 
chemotherapy.161–163 However, dasatinib in combination with 
gemcitabine did not improve overall compared with gemcit-
abine and placebo in locally advanced, non-metastatic PDAC.164 
Another common approach to target upregulated Ephrin signal-
ling is to inhibit the downstream pathways, such as the MAPK 
or PI3K pathways.158 Importantly, as PDAC therapy necessarily 
turns towards predictive biomarkers to guide personalised 
therapies, upregulation of Ephrin family members may predict 
response to RTK, MAPK or PI3K pathway inhibition in PDAC.
Canonical and non-canonical inhibition of aberrant 
transforming growth factor β (TgFβ) signalling
The membrane-bound TGFβ receptor is mutated at a relatively 
low frequency in PDAC.50 70 However, disruptions in other 
pathway components occur in ~47% of patients, including 
mutations in SMAD4, SMAD3, TGFBR1, TFGBR2, ACVR1B 
and ACVR2A.42 There is a complex relationship between TGFβ 
signalling and either tumour suppression or metastatic spread.165 
Indeed, loss of SMAD4 is indicative of a poorer prognosis, while 
TGFβ pathway activation is associated with an epithelial-to-mes-
enchymal transition, one of the driving factors for metastatic 
dissemination.165 166 This has made TGFβ signalling the focus 
of recent clinical trials combining TGFβ receptor inhibition 
with gemcitabine (NCT02154646 and NCT01373164) or 
immunotherapy (NCT02734160). However, these trials are 
not biomarker driven and hence are not stratified for SMAD4 
mutational status, which is associated with failure of adjuvant 
chemotherapies in PDAC.167 168 The role of SMAD4 in TGFβ 
signalling is primarily tumour suppressive, and this function 
may limit application of TGFβ receptor inhibitors, where they 
would best be applied to patients with SMAD4 deletion.169 A key 
non-canonical mediator of TGFβ signalling is the PI3K pathway, 
which was shown to be inhibited by TGFβ receptor inhibitors 
and activated by endogenous TGFβ.165 170 171 Hence, an alterna-
tive route, independent of the tumour-suppressive functions of 
TGFβ signalling, may be through inhibition of these non-canon-
ical signalling pathways.
Targeting dnA damage repair defective tumours
Aberration in DNA damage repair pathways, such as mutations in 
BRCA1, BRCA2, PALB2 or ATM, are commonly associated with 
increased risk of familial pancreatic cancer,172 173 but also occur 
in the later stages of PanIN development and PDAC.18 20 42 56 
Loss of these DNA repair proteins leads to genomic instability 
and predisposes patients to breast, ovarian, prostate and pancre-
atic cancers.174–176 Patients with mutations in this pathway in 
other cancers have shown beneficial responses to PARPi, and 
recent clinical trials in PDAC have been performed to assess 
the beneficial role of second-line olaparib monotherapy in 
BRCA1/2-deficient patients, following failure on gemcitabine.177 
PARPi work on the basis of synthetic lethality whereby tumours 
with defects in double-stranded DNA repair pathways become 
dependent on PARP to repair the resultant collapsed replication 
forks and maintain chromosomal stability and cell cycle progres-
sion.178–180 Another option for patients with mutations in DNA 
repair pathways is by causing further DNA damage in these 
defective cells by either platinum-based therapies or mitomycin 
C.56 181 Furthermore, the PI3K pathway has a well-established 
role in DNA damage repair, and promising combination ther-
apies in endometrial and breast cancers have motivated clinical 
trials in PDAC to assess the effect of PARPi in combination with 
PI3K pathway inhibitors (table 2, figure 3).182–184 The clear 
responses seen in patients presenting with these DNA repair 
defects provides a promising personalised approach to therapy 
when standard of care is found to be ineffective.
sensitisation of cell cycle defective tumours to cyclin-
dependent kinase (Cdk) inhibitors as combination therapy
Mutations in CDKN2A, CCND1 and/or CDK4/6 commonly 
occur in PDAC, and recent work has demonstrated that the 
reliance of some tumours on this pathway may sensitise them 
to CDK inhibitors (CDKi).50 In recent work, the sensitivity of 
a panel of PDCLs was assessed for their response to a CDKi, 
which identified PDCLs with high expression of retinoblas-
toma protein and low expression of p16INK4A were significantly 
correlated with improved response to CDKi, in combination 
with gemcitabine.185 This is in line with work in breast and 
ovarian cancers, and melanoma, where this same expression 
pattern is common.186–188 Furthermore, it has been shown that 
in PDAC and other cancers, combinations of CDKi with PI3K 
pathway inhibition in subsets of patients can have an even 
greater response, thus stratification in this setting may warrant 
further investigation (table 2).189 190
histone deacetylases (hdACs) and mutant p53 inhibitors
Loss or mutation of the tumour suppressor p53 occurs in ~75% 
of patients with PDAC, where gain-of-function mutations occur 
at a higher prevalence and are thought to provide a growth 
advantage, as well as driving metastatic progression.50 191 192 The 
primary role of p53 is to bind DNA as a transcriptional acti-
vator or repressor, mediating transcriptional networks respon-
sible for cell death and replicative senescence in response to 
genotoxic or oncogenic stress.193 194 HDACs work by regulating 
gene expression at an epigenetic level and have been associated 
with upregulation of mutant p53 in several cancers, including 
PDAC.195 196 Furthermore, several HDACs are overexpressed in 
PDAC, prompting assessment of the clinical benefit of their inhi-
bition.197 198 Recently, a phase I clinical trial of vorinostat with 
chemoradiation in PDAC showed promising overall survival 
benefits.199 In parallel, emerging studies in other AdvSTs demon-
strated promising synergistic benefits when combining vorinostat 
with the broad-spectrum RTKi sorafenib200 201 and subsequently 
led to a new phase I trial of vorinostat and sorafenib with chemo-
therapy in PDAC (NCT02349867).
One of the key mediators of p53 protein stability is mouse 
double minute 2 (MDM2), which is responsible for ubiquitina-
tion and subsequent degradation of p53 by the proteasome.202 
Mutation of CDKN2A occurs in 35% of PDAC tumours leading 
to loss of expression of the tumour suppressors p16INK4a and 
p14ARF (p19ARF in murine tumours).50 ARF inhibits MDM2, and 
hence loss of this tumour suppressor leads to increased levels of 
MDM2 and a decrease in p53 pathway activity.203 Another key 
mediator of MDM2 activation is Akt, which activates MDM2 
in parallel with other survival pathways (figure 3).61 Further-
more, the tumour suppressor PTEN has been shown to bypass 
MDM2 and stabilise p53 protein levels, leading to downstream 
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activity.204 205 In the complex mutational landscape of PDAC, it 
is unclear how PI3K pathway inhibitors may affect the already 
overexpressed levels of mutant p53.206 However, ~26% of 
PDAC tumours retain wild-type p53, and recent work demon-
strated that MDM2 inhibitors were able to reactivate wild-type 
p53 pathway signalling in pancreatic cancer.207 This may suggest 
that PI3K pathway inhibition in PDAC could reduce MDM2 
levels and facilitate activation of the tumour-suppressive func-
tions of p53 and lead to apoptosis.208 209 Caution may need to be 
taken however, for patients with p53 mutations where upregula-
tion of this mutant protein may enhance tumourigenesis.210 The 
complex relationship between these pathways includes GSK-3β, 
which has been implicated in MDM2 activation and p53 degra-
dation.211 212 GSK-3β is a canonical Akt substrate and is inac-
tivated by this phosphorylation interaction (figure 3).61 This 
complex regulation of MDM2 by different members of the PI3K 
pathway may explain the complex responses of p53 wild-type 
or deficient tumours when applying PI3K pathway inhibitors as 
radiosensitising agents.213–216
development of small molecule inhibitors for oncogenic 
kRAs and MAPk signalling
Mutations in KRAS occur in ~95% of PDAC cases, and this has 
prompted several efforts to target both mutant KRAS and the 
resultant aberrant downstream signalling.26 38 The predominant 
KRAS mutations in PDAC are KRASG12D and KRASG12V, where 
KRAS G12D accounts for 83% of KRAS mutations in PDAC and 
has been shown to classify into more aggressive molecular 
subtypes.41 217 This aggressive classification may be due to the 
downstream signalling cascades that have been linked to specific 
KRAS mutants, where KRASG12D predominantly activates the 
MAPK and PI3K pathways, whereas KRASG12V predominantly 
activates Ral signalling.218 Several attempts have been made to 
inhibit oncogenic Ras isoforms by either competitive inhibition 
of GTP binding or by preventing membrane translocation but 
have so far failed to successfully inhibit Ras at a low enough dose 
for clinical efficacy.217 Similarly, the farnesyl transferase inhib-
itor, tipifarnib, did not prolong overall survival compared with 
gemcitabine alone in advanced PDAC.219 Interestingly, RNA 
interference approaches have been efficaciously applied to PDAC 
tumours that were metabolically reprogrammed by mutant Ras, 
where inhibition of the mutant isoform was sufficient to delay 
tumour growth.220–222 With this in mind and by successfully 
delivering small inhibitory RNAs (siRNAs), one group was able 
to demonstrate the in vivo application of a miniature biode-
gradable polymeric matrix for delivery of a KRASG12D-targeted 
siRNA.221 Knockdown of oncogenic KRASG12D at the transcript 
level effectively inhibited downstream pathways and reduced in 
vivo tumour burden. Another recent approach to deliver siRNAs 
against oncogenic KRASG12D to PDAC tumours is using fibro-
blast-derived exosomes, termed iExosomes, which maintain 
CD47 expression and hence show increased bioavailability and 
tumour uptake.220
As an alternative approach to inhibition of oncogenic KRAS, 
innumerable inhibitors have been developed to target the key 
signalling cascades immediately downstream, namely the MAPK 
and PI3K pathways. Several clinical trials have been performed 
using MEKi in combination with gemcitabine,223 224 but these 
have so far failed to demonstrate significant improvements 
in survival, compared with gemcitabine alone. Inhibition of 
the MAPK pathway is regularly associated with an increase in 
PI3K pathway activity.225 226 Hence, new treatment strategies 
have emerged that aim at inhibiting both of these key effector 
pathways (table 2). While these follow from promising preclin-
ical studies, where the combined efficacy of dual MAPK and 
PI3K pathway inhibition provides significant tumour growth 
inhibition, the combined toxicity of this approach can present 
a strong limiting factor.226 227 Notably, the sequential effect of 
targeting these pathways may increase tumour susceptibility to 
inhibition while potentially minimising toxicity.228
MICRoenvIRonMenTAl InFluenCes on dRug ResPonse
PDAC is characterised by a highly desmoplastic reaction, 
commonly associated with high levels of stromal infiltration, 
ECM deposition and tumour hypoxia.47 229 Targeting of the 
ECM or associated stroma has shown some efficacy in PDAC, 
by improving drug delivery and sensitising tumours to chemo-
therapy,230–232 although the viability of targeting the stroma 
in PDAC remains controversial. Complete stromal ablation in 
PDAC was shown to enhance cancer aggressiveness,233 234 which 
calls for more subtle and targeted approaches to normalising 
instead of completely ablating the tumour-associated stroma.47 235 
This effect is partly thought to occur due to a normalisation of 
the tumour vascular network and manipulation of the ECM/
stroma, improving drug efficacy in the tumour.231 235 236 Another 
common feature resultant from enhanced desmoplasia is the 
development of a hypoxic environment (figure 4). Hypoxia is 
strongly associated with increased radioresistance, chemoresis-
tance and metastasis,237–239 and PDAC is among those cancers 
with a propensity for high levels of tumour hypoxia, which is 
predictive of poorer patient prognosis.229 240
Reduced oxygen consumption and increased glycolysis were 
recently identified by mitochondrial genome sequencing in 
PDAC PDCLs.241 This is a key aspect of the Warburg effect, which 
predicts tumours to rely more heavily on glycolysis for their 
metabolism.242 While this presents an advantage for tumours 
that experience reduced vascularity and oxygen levels, it also 
presents an opportunity to potentially starve the tumour in these 
hypoxic regions.243 One of the first steps for tumours to switch 
to glycolytic metabolism is an increase in lactate dehydrogenase 
(LDH) activity, which converts pyruvate into lactate.244 Inhibi-
tion of LDH has recently been shown to synergise with gemcit-
abine in vitro and may provide a novel strategy for PDAC.245 
Another important aspect of PDAC metabolism is the metabolic 
reprogramming resultant from KRAS mutation, which upregu-
lates glucose uptake and biomass synthesis.246 Furthermore, the 
upregulation of MUC1 during PDAC progression, along with 
HIF1α in hypoxic tumour regions, has been shown to coop-
erate by upregulating anabolic metabolism through the pentose 
phosphate pathway, resulting in gemcitabine resistance.247 The 
glycolytic switch in hypoxia can lead to a decrease in pH, and 
hence pH-regulating proteins are also an important downstream 
target of the cellular hypoxic response.248 Inhibitors of these 
pH-regulatory components are currently being assessed, after 
promising preclinical work, for their role in limiting tumour 
growth.249 250 The PI3K pathway also plays an important role in 
glucose uptake, amino acid metabolism and response to cellular 
stress.58 60 61 In hypoxia, Akt activity is upregulated, along with 
glucose transporters, to facilitate the switch to anaerobic metab-
olism.105 214 238 243 Moreover, treatment of PDAC with PI3K 
pathway inhibitors is less effective in hypoxia, highlighting an 
important microenvironmental consideration for future strati-
fied clinical trials.105 251
With this in mind, we recently demonstrated that a hypox-
ia-activated prodrug (HAP) could alleviate hypoxia-induced 
resistance to a PI3K pathway inhibitor in a combination 
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therapy.105 HAPs are typically metabolised by enzymatic reduc-
tion in hypoxia from a primarily inactive form to an active form 
while having limited effects on normoxic or healthy tissues, 
making them ideal for development of combination therapies 
(figure 4; reviewed in ref 238). This approach was also found 
to be effective in renal cell carcinoma, where combination with 
rapalogs and the HAP TH-302 significantly improved survival 
in preclinical models.252 The efficacy of these HAPs began to 
be realised with tirapazamine, which showed a high differen-
tial toxicity in hypoxia, compared with normoxia, which made 
it an ideal candidate for combination with radiotherapy.253 254 
However, despite promising phase II clinical trials in squamous 
cell carcinoma, a phase III trial failed to show improved efficacy 
over chemoradiotherapy alone.255 Notably, this trial was not 
biomarker driven and hence did not stratify patients based on 
hypoxic tumour burden, which may have disguised any potential 
efficacy in a subset of patients. This is a common issue in clinical 
trials and is also implicated in the phase III failure of TH-302 
after promising phase II results (NCT01746979).256 The preclin-
ical promise and potential applications of HAPs in combination 
therapies means that despite the phase III setbacks, improved 
tirapazamine analogues, such as SN3000 and SN29751, as well 
as other recently developed HAPs, including PR-104 and AQ4N, 
are all under preclinical/clinical investigation.257–259
Recent work by our group demonstrated that a hypoxic gene 
signature was associated with a poorer prognosis for patients 
with PDAC.229 While this is a promising approach, application 
in the clinic may be limited by the collection of patient biop-
sies, which may not adequately represent the extent of hypoxia 
within the whole tumour. The necessary stratification of patients 
for future clinical trials calls for a method to assess the whole 
tumour non-invasively (figure 2). To this end, positron emis-
sion tomography approaches have been developed based on 
radiolabelled 2-nitroimidazoles or antibodies, which can be 
coupled with 18F–fluorodeoxyglucose imaging to first identify 
malignant lesions.238 Similarly, non-invasive imaging of oxygen 
partial pressure using electron paramagnetic resonance imaging 
or assessment of pyruvate metabolism by MRI have also been 
used to stratify PDAC tumours for treatment with TH-302 and 
radiation.260
Moving forward, the design and synthesis of HAPs with 
defined molecular targets are emerging for specific applications. 
For example, hypoxia-activated chk1 inhibitors were recently 
developed as proof-of-principle molecules for targeting the 
hypoxic compartment of tumours, where chk1 is an important 
component of the DNA damage response and cell cycle progres-
sion.261 From these studies, it is clear that the emerging appli-
cation of microenvironmental-targeted agents in combination 
therapies can improve patient outcomes, and as newer genera-
tion inhibitors are developed, we are likely to see a wider appli-
cation of these agents entering the clinic.
ConClusIons
Given the lagging improvements in therapy, there is a dire need 
to find new biomarkers and targets to move pancreatic cancer 
towards personalised medicine approaches (figure 2). To guide 
clinical success, emerging combinations would benefit from a 
preclinical platform of evidence in at least one in vivo model, 
as well as optimisation of solubility for reduced toxicity and, 
importantly, identification of at least one suitable biomarker for 
Figure 4 Schematic of the formation of a hypoxic environment and the potential targeting of this microenvironment with HAPs. RBCs transport 
oxygen through the blood vasculature, and hypoxia forms when this diffusion-limited process delivers insufficient oxygen to cells distant to 
the vasculature (blue cells). The extreme case of anoxia (grey cells) regularly results in necrotic cell death. HAPs take advantage of the hypoxic 
environment of tumours to deliver cytotoxic compounds to these tumour regions, where the prodrug is either enzymatically cleaved by the cells 
metabolic machinery or undergoes a conformational change in response to the low oxygen partial pressure. HAPs, hypoxia-activated prodrugs; RBCs, 
red blood cells.
box 2 what may improve clinical trials?
 ► Patient subtyping from tumour biopsies by genomic and/or 
mass spectrometry approaches.
 ► Biomarker identification prior to progression to phase II/
III studies to ensure appropriate patient stratification 
for maximal benefit (circulating cell-free DNA/genomic 
approaches/IHC).
 ► Incorporation of non-invasive imaging for hypoxic 
tumour burden, such as electron paramagnetic resonance 
imaging, MRI or positron emission tomography with 
18F-fluorodeoxyglucose.
 ► Testing of promising lead compounds against stratified 
patient-derived xenograft/Avatar cohorts prior to phase I 
clinical trials.
 ► Development of new prodrugs to use in combination 
therapies with reduced off-target effects.
 ► Raising the bar when defining preclinical ‘success’.
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patient stratification at the level of clinical trials (figure 2). The 
emerging efficacy of PI3K pathway inhibitors for PDAC and the 
convergence of several aberrantly expressed signalling cascades 
highlights a clear progression towards their application for this 
disease. For example, patients with aberrant DNA damage repair 
pathways have responded well to PI3K pathway inhibition as 
part of combination therapies, and trials are already underway 
in PDAC. Furthermore, given the complex dimerisation of 
the ErbB family of RTKs and the association of Ephrin recep-
tors with more aggressive PDAC subtypes, RTKs may provide 
biomarkers for patients that would respond efficaciously to PI3K 
pathway inhibition. Moving forward, one of the key goals of 
the ICGC2 is to link bioinformatics approaches, such as molec-
ular subtyping of patients, to clinical data, and we expect this to 
drive an increase in biomarker-driven clinical trials (proposed in 
box 2). This is a necessary step to decrease the attrition of lead 
compounds in the pharmaceutical industry and to ensure that 
next-generation inhibitors progress to patients that are appro-
priately subtyped for maximum benefit.
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